InflaRx
Daniel has joined InflaRx in July 2022 as Head of IT. He has 15 years of IT management experience with roles such as Head of IT at Vita 34, a stock-listed pharmaceutical company. He started his career as an IT consultant, then worked for various IT and Biotechnology companies and the European Energy Exchange before landing at InflaRx.
He received a Business Administration degree with a focus in Business Informatics and Statistics from the University of Leipzig.
This person is not in any offices
InflaRx
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a.